The lipid-coupled compound is directly modified at the end or middle of the siRNA using a group-mediated delivery that penetrates the cell membrane, allowing the siRNA to be stably and safely delivered to the target cells in vivo.

General Formula:

Lipid coupling delivery platform (LCDP) has the following features:

● It has been applied to siRNA drugs. Pre-clinical subcutaneous injection test has been finished. It has high efficiency, stability and good biodegradability.

● May be used topically or in combination with other therapeutic drugs.

● Combined with CAR-T technology, it can be applied to cancer treatment.

● The mediated compounds can be produced in bulk and sold commercially.